Stockwinners Market Radar for January 06, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:39 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. In a tweet, President Donald Trump said that, "Drug makers and companies are not living up to their commitments on pricing. Not being fair to the consumer, or to our Country!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). 2. Apple (AAPL) and Samsung (SSNLF) announced a deal, under which the iPhone maker will begin offering iTunes movies and TV shows on Samsung TV sets, according to Bloomberg. 3. Last summer when Apple shares soared, analysts kept raising their price targets to higher and higher levels, but this week after the company dropped a guidance bombshell, many of the same analysts slashed their forecasts, Tae Kim wrote in this week's edition of Barron's. In the end, investors are better off holding on anyway, he contended. While Apple's stock performance is currently tied to iPhone sales, its future is tied to a lucrative installed base that's estimated to be 1.3B devices, and CEO Tim Cook needs to find a better way to monetize that base with more services revenue, the publication added. 4. AT&T (T) subsidiary Warner Bros' "Aquaman" stayed atop the chart in its third weekend with $30.7M for a North American total of $259.7M and a global tally of $940.7M. Directed by James Wan, "Aquaman" stars Jason Momoa in the titular role alongside Amber Heard, Willem Dafoe, Patrick Wilson and Dolph Lundgren. The film earned an A- CinemaScore and sports a 64% Rotten Tomatoes score. 5. Air Lease (AL), AT&T, DXC Technology (DXC), Morgan Stanley (MS), Mylan (MYL), and Navistar (NAV) saw positive mentions in Barron's.

17:46 EDT Gilead, Yuhan Corp announce collaboration, license agreement - Gilead Sciences and Yuhan Corporation announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis. Under the agreement, Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, with the exception of the Republic of Korea where Yuhan will retain certain commercialization rights. Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development. Gilead will also be responsible for commercialization worldwide, outside of Yuhan's rights in the Republic of Korea. In connection with this agreement, Yuhan will receive an upfront payment of $15M and is eligible to receive up to an additional $770M in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on future net sales. This agreement builds on the companies' existing commercial collaboration to support the promotion of Gilead's medicines in the Republic of Korea.

17:41 EDT Syros announces strategic priorities, milestones ahead of JPMorgan conference - Syros Pharmaceuticals outlined its strategic priorities and expected upcoming milestones. The Company will review these priorities in a presentation at the 37th Annual JPMorgan Healthcare Conference on Thursday, January 10, 2019. The company expects to complete enrollment in mid-2019 in the ongoing Phase 2 study cohort evaluating the safety and efficacy of SY-1425 in combination with azacitidine in RARA and IRF8 biomarker-positive patients with newly diagnosed acute myeloid leukemia who are not suitable candidates for standard chemotherapy. Syros also expects to report updated clinical data in the second half of 2019 on SY-1425 in combination with azacitidine, and report initial clinical data in the fourth quarter of 2019 from the expansion portion of the ongoing Phase 1 trial, which is assessing SY-1365 as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations. Additionally, the company expects to complete IND-enabling studies to support initiation of a Phase 1 oncology trial in early 2020. Syros also announced that it has made a portfolio prioritization decision not to pursue further development of SY-1425 in combination with daratumumab beyond completion of the ongoing pilot cohort in the Phase 2 trial. Based on its current operating plans, Syros expects that its existing cash, cash equivalents and marketable securities will enable it to fund its anticipated operating expenses and capital expenditure requirements into 2020. Syros had approximately $113.2M in cash, cash equivalents and marketable securities as of September 30, 2018.

16:20 EDT Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis - Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of '1690 in patients with systemic sclerosis. NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases. One of the most visible manifestations is hardening of the skin. In diffuse cutaneous SSc, skin thickening affects several body areas, and patients have a higher risk of developing fibrosis of various internal organs, such as the lung. Currently, there are no approved drugs for this disease. SSc affects approximately 90,000 patients in the US and Europe, with a predominance of female patients. The primary endpoint of NOVESA is the modified Rodnan skin score at 24 weeks. mRRS measures the skin thickness as a surrogate measure of disease severity and mortality, with an increase in thickness associated with involvement of internal organs and increased mortality. Secondary objectives and exploratory endpoints include FVC, HRCT, quality of life as measured by QoL-Q, and CRISS, a SSc disease composite score.

12:52 EDT Elbit Systems awarded $333M contract from Israeli Ministry of Defense - Elbit Systems has announced that it was awarded a contract by the Directorate of Production and Procurement of the Israeli Ministry of Defense valued at approximately $333M for the supply of ammunitions to the Israeli Defense Forces. This five-year contract, the work on which will commence in 2026, will be a continuation of a multi-year contract entered to with the IMOD.